

Combination of alpha-1-acid glycoprotein and
Alpha-fetoprotein as an improved diagnostic tool
for hepatocellular carcinoma

Thesis

Submitted for Partial Fulfillment of Master Degree
in Internal Medicine

Presented by

Moustafa Ahmed Hassan

M.B.B.CH

Faculty of medicine – Ain Shams University

Supervisors

Prof. Dr. Samir AbdElHamid Ghait

Professor of internal medicine

Faculty of Medicine, Ain Shams University

Dr. Ghada Amer Farghaly

Assistant Professor of internal medicine

Faculty of Medicine, Ain Shams University

Dr. George Safwat Riad

Lecturer of internal medicine

Faculty of Medicine, Ain Shams University

Faculty of medicine

Ain Shams University

2011

الجمع بين ألفا- ١ -أسيد جليكو بروتين وألفا-
فيتوبروتين، لتشخيص أفضل
لسرطان الكبد الاولي
رسالة

توطئة للحصول علي درجة الماجستير في الباطنة العامة

مقدمة من
الطبيب / مصطفى احمد حسن.

المشرفين
الأستاذ الدكتور / سمير عبد الحميد غيط
أستاذ الباطنة العامة
كلية الطب ، جامعة عين شمس

الدكتور / غادة عامر فرغلي
أستاذ مساعد الباطنة العامة
كلية الطب ، جامعة عين شمس

دكتور / جورج صفوت رياض
مدرس الباطنة العامة
كلية الطب ، جامعة عين شمس.


كلية الطب
جامعة عين شمس
٢٠١١

Summary

Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide. It is a major health problem and its incidence is increasing. The presence of cirrhosis of the liver is the major risk factor and worldwide this is largely due to chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection. The diagnostic modalities, especially with respect to hepatic imaging, have improved in recent years. This, along with HCC surveillance in patients with cirrhosis, has led to the detection of HCC at an earlier stage, when curative therapy is likely to be more successful. The major diagnostic techniques for HCC include serum markers, various imaging modalities and histological analysis (*Gomaa et al., 2009*). According to recent reports, the incidence of HCC has increased sharply in the last 5–10 years, with an especially high incidence in Egypt (*Anwar et al., 2008*).

The main goal of our study was to evaluate the role of AAG in the diagnosis of HCC in combination with alpha-fetoprotein which is the most widely used tumor marker for diagnosis as well as surveillance of HCC.

The study was performed on 40 patients recruited from the Internal Medicine & Hepatology Department, Ain Shams University Hospitals. Patients were classified into 2 groups; **Group I** consisted of 20 HCC patients, their ages are



Acknowledgement

All praise be to Allah and all thanks. Allah has guided and enabled me by His mercy to fulfill this thesis, which I hope to be beneficial for people.

I would like to express my deepest gratitude and sincere appreciation to Prof. Dr. Samir Abd Elhamid Git, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University for his continuous encouragement, his kind support and appreciated suggestions that guided me to accomplish this work.

I am also grateful to Dr. Ghada Amer Farghaly, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University who freely gave her time, effort and experience along with continuous guidance through out this work.

Special thanks are extended to Dr. George Safwat Riad, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University for his constant encouragement and advice whenever needed.

I am sincerely grateful to all patients who are participated in this research work hoping for them and for all Hepatic patients better care and Health.

I am deeply indebted for my mother for her support, patience and encouragement.

Moustafa Ahmed Hassan

List of Contents

Introduction	1
Aim of the work	3
Review of literature:	
Chapter (1): Epidemiology	4
Chapter (2): Pathology	17
Chapter (3): Diagnosis and surveillance	22
Chapter (4): Staging	42
Chapter (5): Treatment	58
Chapter (6): Prevention	78
Chapter (7): Alpha fetoprotein	101
Chapter (8): Alpha-1-acid glycoprotein	105
Patients and Methods	108
Results	118
Discussion	148
Summary	165
Conclusion	168
Recommendations	169
References	170
Master Sheet	224
Arabic Summary	—

Abbreviations

AAG	Alpha 1 acid Glycoprotein
AASLD	American Association for the study of the liver disease
AFB-FABY	AFB1-formamido pyrimidine adduct
AIDS	Acquired immune deficiency syndrome
AFB1	Aflatoxin B1
AFP	Alpha-fetoprotein
AFPIC	Alpha-fetoprotein immunocomplexes
AFP L3	Lens culinaris agglutinin reactive alpha fetoprotein
AFU	Alpha-L-fucosidase
AJCC	The American Joint Committee of Cancer
AKT	(PKB) protein kinase B
ALT	Alanine transaminase
AUC	Area under curve
AST	Aspartate transaminase
BCLC System	The Barcelona-Clinic- Liver-Cancer system
CP	Child- pugh
CTP	Child –pugh -Turcotte
CECT	Contrast enhanced helical computed tomography
CEUS	Contrast enhanced ultrasound
CLD	Chronic liver disease
CLIP	The Cancer of the Liver Italian Program
CT	Computed tomography
CUPI	Chinese University Prognostic Index
CYP	Cytochrome P
DCP	Des-gamma carboxyprothrombin
DGCP	Des-gamma -carboxyprothrombin
DNA	Deoxyribonucleic acid
EASL	European association for the study of the liver
EDTA	Ethylenediaminetetraacetic acid
EGFR	Epidermal growth factor receptor
ELISA	Enzyme-linked immunosorbent assay
EPI	Expanded program of immunization
ESR	Erythrocyte sedimentation rate
FDA	Food and Drug Administration

F-FDG	F-flurodeoxyglucose
FNAB	Fine needle aspiration biopsy
HA	Hepatic artery
HBIG	Hepatitis B immunoglobulin
HBV	Hepatitis B virus
HBsAG	Hepatitis B surface anrigen
HBeAG	Hepatitis B e anrigen
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HFL	Hepatic focal lesion
HH	Hereditary Haemochromatosis
HE	Hepatic encephalopathy
HIV	Human immune deficiency syndrome
HIFU	High intensity focused ultrasound
HMG CoA reductase	Hydroxy methyl glutaryl coenzyme A reductase
HMRS	Proton Magnetic Resonance Spectroscopy
ICG	Indocyanine Green
ICG R15(%)	Indocyanine Green retention rate at 15 minutes
IGF	Insulin like growth factor
IQR	Interquartile range
IFN	Interferon
IRS-1	Intracellular receptor substrate - 1
ITRAQ	sobaric tags for relative and absolute quantitation
INR	International normalized ratio
JIS Score	The Japan Integrated Staging score
KEAP1	Kelch-like ECH-associated protein 1
LCSGJ	The Liver Cancer Study Group of Japan
LDH	Lactate dehydrogenase
LT	Liver Transplantation
MAF	Macrophage activating factor
MDCT	Multidetector helical CT
MELD	The Model for End Stage Liver Disease
mJIS	The modified Japan Integrated Staging
mTOR	Mammalian targeted of rapamycin
MPCT	Multiphasic helical CT
MRI	Magnetic resonance imaging

NASH	Nonalcoholic steatohepatitis
NAFLD	Non alcoholic fatty liver disease
NPV	Negative predictive value
NRV	Nuclear receptor factor
OLT	Orthotopic liver transplantation
OS	Overall survival
PAT	Parenteral anti-schistosomal treatment
PBC	Primary biliary cirrhosis
PC	Prothrompin concentration
PI3K	Phosphatidyl inositol-3-kinase
PIVKA-II	Protein induced by vitamin K absence or antagonist II
PAHO	Pan American Health Organization
PET	Positron emission tomography
PPV	Positive predictive value
PS	Performance status score
PSC	Primary sclerosing Cholangitis
Ras	Rat Sarcoma
RCT	Randomized Controlled Trial
ROC	The receiver operating characteristic curve
SD	Standard Deviation
SELDI-TOF	Surface-enhanced laser desorption/ionization-time of flight mass spectrometry
SLiDe	S : stage - Li : liver damage – De : des- γ -carboxy prothrombin
TNM Staging System	Tumor, Node and Metastases Staging System
TPO	Human thrompoietin
UNOS	United Network of Organ Sharing
US	Ultrasonography
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VSV	Vesicular Stomatitis virus
WHO	World Health Organization

List of Figures

Figure (I):	HCC. B-mode US demonstrates a heterogeneous hypoechoic solid liver lesion (arrow) in segment IV, confirmed to be HCC	30
Figure (II):	Hepatocellular carcinoma (HCC). (a) Arterial phase CT (b) Portal venous phase CT	33
Figure (III):	HCC with many typical MRI features	35
Figure (IV):	Detection of HCC with 18F-FDG PET/CT and 11Cacetate PET/CT on transaxial sections of liver and chest	37
Figure (V):	Lack of 18F-FDG-PET for HCC	38
Figure (VI):	Strategy for staging and treatment assignment in patients diagnosed with HCC according to the BCLC proposal	57
Figure (VII):	Multi-pronged Quadrafuse needle. Photo showing the 18G needle with tynes retracted	62
Figure (VIII):	Multi-pronged Quadrafuse needle. Photo showing the tynes fully extended	63
Figure (IX):	Multi-pronged needle. Photo showing set-up of the needle ready for injection	63
Figure (X):	Complete necrosis (100%). 65-year old man with hepatocellular carcinoma in segment 6	64
Figure (XI):	Complete necrosis (100%). 65-year old man with hepatocellular carcinoma in segment 6. Arterial phase of repeat triphasic CT scan 2 – weeks post alcohol injection showing complete necrosis of the lesion with no arterial enhancement during the arterial phase	64
Figure (XII):	Near complete necrosis (90% - 99%). 56-year old man with 8 cm hepatocellular carcinoma in segment 8 of the liver	65

Figure (XIII): MRI-guided Laser and Focused ultrasound ablation	69
--	----

Figures of Results

Figure (1): Age variation between HCC and chronic liver disease group	119
Figure (2): Sex variation between HCC and chronic liver disease group	119
Figure (3): Residence variation between HCC and chronic liver disease group	120
Figure (4): Social habits of medical importance in both groups	120
Figures (5): Work variations in HCC group and chronic liver disease group	121
Figure (6): Medical history of studied groups	122
Figure (7): Shows relation between child scores and both groups	128
Figures (8): ESR Level in HCC group and chronic liver disease group	130
Figure (9): Relation between AAG & versus HE among HCC group	134
Figure (10): Relation between AFP versus HE among HCC group	134
Figure (11): Relation between AAG versus HE among chronic liver disease	136
Figure (12): Relation between AFP versus HE among chronic liver disease	136
Figure (13): Relation between AAG versus CT scan among chronic Liver disease group	137

Figure (14): Relation between AFP versus CT scan among chronic Liver disease group	138
Figure (15): Number of hepatic focal lesions in HCC group	140
Figure (15): Site of hepatic Focal lesions in HCC group	140
Figure (17): Echogenecity of the hepatic focal lesions in HCC group	141
Figure (18): Size of largest HFL in HCC group	141
Figure (19): Triphasic Abdominal CT of HCC patients enhancement	142
Figure (20): AAG level in HCC and chronic liver disease group	144
Figure (21): AAG level in HCC and chronic liver disease group	144
Figure (22): ROC curve of AAG and AFP in HCC patients	145
Figure (23): ROC curve of AAG and AFP in low AFP HCC patients (<200)	146
Figure (24): ROC curve of AAG and AFP in high AFP HCC patients (>200).....	147

List of Tables

Table (I):	EASL consensus diagnostic criteria for HCC	39
Table (II):	AASLD diagnostic criteria for HCC	39
Table (III):	AJCC TNM Staging	44
Table (IV):	UNOS TNM Staging	45
Table (V):	Okuda Staging System	46
Table (VI):	Child-Pugh Score	48
Table (VII):	CLIP Score	49
Table (VIII):	Japan Integrated Staging Score	51
Table (IX):	Liver damage grade	51
Table (X):	Modified Japan Integrated Staging	52
Table (XI):	SLiDe Classification	52
Table (XII):	French classification	53
Table (XIII):	Definitions of CUPI score	54
Table (XIV):	BCLC practical staging of HCC	56
Table (XV):	Overall results of alcohol injection and according to hepatomas size	62

Tables of Results

Table (1):	Demographic features of the studied groups	118
Table (2):	Medical history of studied groups	122
Table (3):	Clinical picture of the patient groups	123

Table (4):	Distribution of HCC group as regard laboratory data	124
Table (5):	Distribution of chronic liver disease group as regard laboratory data	125
Table (6):	Comparison between both studied groups as regard laboratory data	126
Table (7):	Comparison between both studied groups as regard hepatic encephalopathy & ascites	127
Table (8):	Comparison between both studied groups as regard Child classification	128
Table (9):	Correlation between AAG &AFP versus laboratory data and age among HCC group	129
Table (10):	Correlation between AAG &AFP versus laboratory data and age among chronic liver disease group	131
Table (11):	Correlation between AAG versus AFP in low AFP HCC (<200)	132
Table (12):	Correlation between AAG versus AFP in high AFP HCC (>200)	132
Table (13):	Relation between AAG &AFP versus HE among HCC group	133
Table (14):	Relation between AAG &AFP versus HE among chronic liver disease	135
Table (15):	Relation between AAG &AFP versus CT scan among chronic liver disease group	137
Table (16):	Abdominal ultrasonographic findings of the patient groups.....	139

Table (17): Triphasic Abdominal CT of HCC patients	142
Table (18): Comparison between both studied groups as regard AAG and AFP	143
Table (19): Validity of AAG &AFP in diagnosis of HCC	145
Table (20): Validity of AAG &AFP in diagnosis of low AFP HCC (<200)	146
Table (21): Validity of AAG &AFP in diagnosis of high AFP HCC(>200)	147

Introduction

Globally, hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths, and is the fifth most commonly diagnosed solid tumor. The majority of HCC patients occur in sub-Saharan Africa and parts of South East Asia; however, incidence rates appear to be on the rise in developed nations such as the United States, Japan and Western Europe. The lack of HCC biomarkers prevents early detection resulting in a poor prognosis of the disease (*Stefaniuk et al., 2010*).

In Egypt the incidence of HCC has doubled in the last ten years, and it is now the second most incident and lethal cancer in men. The heavy burden of HCC parallels high rates of hepatitis C virus (HCV) while hepatitis B virus (HBV) rates have declined after the introduction of the vaccine in 1992. Nevertheless, the age standardized HBV incidence rate in males (20.6/100, 000) is seven times higher than what is found in the Middle East Cancer Consortium, and more than three times the incidence rates (*Asmis et al., 2010*).

Prognosis and survival of patients with HCC is heavily affected by the disease stage at the time of diagnosis. The availability of reliable markers would greatly improve the chances of detecting early stage HCC. Imaging modalities, such as ultrasonography, are currently limited by their low positive